Estie Mermelstein, MSN, FNP-BC

Researchers studied the impact of current opioid agonist therapy on initiation of chronic hepatitis C virus treatment among a population of individuals who inject drugs.

Researchers attempted to determine if medications for opioid use disorder integrated with infectious disease measures can lead to better infectious disease outcomes.

Investigators compared rates of hepatitis C virus infection and office-based buprenorphine prescribing among rural and urban communities.

Investigators assessed response to vaccination with the Moderna or Pfizer-BioNTech COVID-19 vaccines in pregnant and nonpregnant lactating women.

This ad hoc survey focused on changes in sexual behaviors and utilization of and access to sexual health services by MSM during the COVID-19 pandemic.

Regeneron’s antibody cocktail for COVID-19, REGN-COV2, contains 2 neutralizing antibodies: casirivimab and imdevimab; results from the phase 1/2 trial reveal promising results for patients who were antibody-negative or had high viral loads.